|
|
|
2 | (1) |
| Abbreviations |
|
2 | (1) |
|
Journals And Other References |
|
|
3 | (177) |
|
Table 1A Antiretroviral Therapy Reduces HIV Transmission Risk |
|
|
4 | (5) |
|
1B Assessment of HIV Infection Risks & Recommendations for HIV Testing |
|
|
5 | (4) |
|
Table 2 Initial Evaluation of HIV-infected Adult Patient |
|
|
9 | (1) |
|
Table 3A Laboratory Diagnosis Of HIV in Adults and Children (Age < 2 Yrs) |
|
|
10 | (9) |
|
3B CD4/CD8 T-Lymphocyte Counts In HIV Patients |
|
|
12 | (2) |
|
3C Antiretroviral Drug Resistance Testing in HIV Infection |
|
|
14 | (5) |
|
Table 4A 1993 Revised CDC HIV Classification System & Expanded AIDS Surveillance Definition for Adolescents & Adults |
|
|
19 | (2) |
|
4B Correlation of Complications with CD4 Cell Counts/WHO Clinical Staging System |
|
|
20 | (1) |
|
Table 5A Adult Antiretroviral Therapy (ART): when and what to start |
|
|
21 | (2) |
|
Table 5B Management of Antiretroviral Therapy (ART) failure |
|
|
23 | (2) |
|
Table 6A Selected characteristics of Antiretroviral (ARV) Drugs |
|
|
25 | (30) |
|
6B Antiretroviral Drugs & Adverse Effects |
|
|
35 | (5) |
|
6C Drug Adverse Effects by Clinical Presentation |
|
|
40 | (4) |
|
6D Overlapping Toxicities Between Antiretrovirals and Other Drugs Commonly Used in HIV Patients |
|
|
44 | (1) |
|
6E Anti-HIV Drugs Available Via Expanded Access Programs |
|
|
45 | (1) |
|
6F Antiretrovirals Approved or Tentatively Approved by FDA for International AIDS Relief |
|
|
46 | (4) |
|
6G Liquid Formulations of ART Drugs |
|
|
50 | (5) |
|
Table 7A Acute HIV Infection |
|
|
55 | (4) |
|
7B HIV Exposure Management |
|
|
56 | (3) |
|
Table 8A HIV/AIDS In Women/Pregnancy |
|
|
59 | (22) |
|
8B HIV in the Fetus & Newborn |
|
|
62 | (1) |
|
8C HIV Infection in Children |
|
|
63 | (1) |
|
8D Children: Initial Evaluation, Initiation of Antiretroviral Therapy, PJP Prophylaxis & Supportive Therapy |
|
|
63 | (6) |
|
8E Clinical Syndromes, Opportunistic Infections in Infants & Children, which Differ from Adults |
|
|
69 | (2) |
|
8F Selected Drugs Commonly Used in Children with HIV Infection |
|
|
71 | (9) |
|
8G Prophylaxis for First Episode of Opportunistic Disease in HIV-infected Infants & Children |
|
|
80 | (1) |
|
Table 9 HIV-HCV Co-Infection |
|
|
81 | (1) |
|
Table 10 Primary Prophylactic Antimicrobial Agents Against Opportunistic Pathogens in Adolescents & Adults |
|
|
82 | (1) |
|
Table 11A Diagnosis & Differential Diagnosis of Clinical Syndromes, Opportunistic Infections & Neoplasms |
|
|
83 | (33) |
|
11B Immune Reconstltutlon Inflammatory syndrome (IRIS) |
|
|
113 | (1) |
|
11C Novel Syndromes After Starting ART |
|
|
114 | (2) |
|
Table 12 Selected Common Ols or Problematic Infections |
|
|
116 | (20) |
|
Table 13 Drugs Used in Treatment &/or Chronic Suppression of AIDS-Related Infections: Adverse Effects, Comments |
|
|
136 | (9) |
|
Table 14A Selected Pharmacologic Features of Antimicrobial Agents Used in HIV-Associated infections in Adults |
|
|
145 | (8) |
|
14B Cytochrome P450 Interactions of Antimicrobials |
|
|
152 | (1) |
|
Table 15A Dosage of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
153 | (7) |
|
15B No Dosage Adjustment with Renal Insufficiency |
|
|
159 | (1) |
|
15C Dosage of Antiretroviral Drugs in Patients with Impaired Hepatic Function |
|
|
159 | (1) |
|
Table 16A Drug/Drug interactions: Antiretroviral Drugs & Drugs Used in Treatment of HIV-Associated infections & Malignancies |
|
|
160 | (8) |
|
16B Drug-Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, CCR-5 Antagonist |
|
|
167 | (1) |
|
Table 17 Antimicrobics in Pregnancy |
|
|
168 | (2) |
|
Table 18 Spectrum & Treatment Of HIV/AIDS-Associated Malignancies |
|
|
170 | (2) |
|
Table 19 Recommendations for Routine Immunization of HIV + Children |
|
|
172 | (1) |
|
Table 20 Immunization of HIV + Adults |
|
|
173 | (2) |
|
Table 21A Measures to be Taken by Physicians in Preparing HIV + Patients & Individuals Likely to Have `Risky' Behavior for Overseas Travel |
|
|
175 | (1) |
|
21B Immunization of HIV+ Adults Traveling to Developing Countries |
|
|
176 | (1) |
|
Table 22 Stimulating RBCs, WBCs & Platelets In HIV Patients |
|
|
176 | (1) |
|
Table 23 AIDS Information & Referral Services |
|
|
177 | (1) |
|
Table 24 List of Generic & Common Trade Names |
|
|
178 | (2) |
| Index |
|
180 | |
